Dermapharm Holding Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Hans-George Feldmeier
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5.6yrs |
| CEO ownership | n/a |
| Management average tenure | 3yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO
Hans-George Feldmeier
5.6yrs
Tenure
Dr. Hans-George Feldmeier is the Chief Executive Officer and Chairman of the Management Board at Dermapharm Holding SE and also serves as Member of the Management Board from August 2017.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Management Board | 5.6yrs | no data | no data | |
| CFO & CCO | less than a year | no data | no data | |
| Member of the Management Board & Chief Business Development Officer | 5.6yrs | no data | no data | |
| Head of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Marketing Officer | less than a year | no data | no data |
3.0yrs
Average Tenure
Experienced Management: DMPH.F's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Supervisory Board | 5.2yrs | €80.00k | no data | |
| Chairman of the Supervisory Board | 5.6yrs | €80.00k | no data | |
| Vice Chairman of the Supervisory Board | 5.6yrs | €80.00k | no data |
5.6yrs
Average Tenure
Experienced Board: DMPH.F's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/12 12:00 |
| End of Day Share Price | 2022/12/13 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dermapharm Holding SE is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Daniel Wendorff | Commerzbank AG |
| Fabian Piasta | Jefferies LLC |